The stock price of Pacira BioSciences Inc (NASDAQ: PCRX) has plunged by -2.53 when compared to previous closing price of 19.80, but the company has seen a 0.16% gain in its stock price over the last five trading sessions. accesswire.com reported 2024-12-13 that NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. (“Pacira BioSciences, Inc.”) (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
Is It Worth Investing in Pacira BioSciences Inc (NASDAQ: PCRX) Right Now?
PCRX has 36-month beta value of 0.79. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 4 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PCRX is 44.58M, and currently, short sellers hold a 10.76% ratio of that float. The average trading volume of PCRX on December 13, 2024 was 782.57K shares.
PCRX’s Market Performance
PCRX’s stock has seen a 0.16% increase for the week, with a 17.33% rise in the past month and a 43.07% gain in the past quarter. The volatility ratio for the week is 4.70%, and the volatility levels for the past 30 days are at 5.19% for Pacira BioSciences Inc The simple moving average for the last 20 days is 7.38% for PCRX stock, with a simple moving average of -12.07% for the last 200 days.
Analysts’ Opinion of PCRX
Many brokerage firms have already submitted their reports for PCRX stocks, with Truist repeating the rating for PCRX by listing it as a “Sell.” The predicted price for PCRX in the upcoming period, according to Truist is $8 based on the research report published on August 13, 2024 of the current year 2024.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see PCRX reach a price target of $14, previously predicting the price at $37. The rating they have provided for PCRX stocks is “Sector Perform” according to the report published on August 12th, 2024.
PCRX Trading at 11.81% from the 50-Day Moving Average
After a stumble in the market that brought PCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.31% of loss for the given period.
Volatility was left at 5.19%, however, over the last 30 days, the volatility rate increased by 4.70%, as shares surge +18.20% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +21.77% upper at present.
During the last 5 trading sessions, PCRX rose by +0.42%, which changed the moving average for the period of 200-days by -34.89% in comparison to the 20-day moving average, which settled at $17.98. In addition, Pacira BioSciences Inc saw -42.80% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PCRX starting from GAUGLER DARYL, who proposed sale 500 shares at the price of $19.76 back on Dec 13 ’24. After this action, GAUGLER DARYL now owns shares of Pacira BioSciences Inc, valued at $9,880 using the latest closing price.
GAUGLER DARYL, the Chief Operating Officer of Pacira BioSciences Inc, sale 500 shares at $12.86 during a trade that took place back on Sep 13 ’24, which means that GAUGLER DARYL is holding 115,700 shares at $6,430 based on the most recent closing price.
Stock Fundamentals for PCRX
Current profitability levels for the company are sitting at:
- -0.09 for the present operating margin
- 0.68 for the gross margin
The net margin for Pacira BioSciences Inc stands at -0.13. The total capital return value is set at -0.05. Equity return is now at value -11.48, with -5.94 for asset returns.
Based on Pacira BioSciences Inc (PCRX), the company’s capital structure generated 0.44 points at debt to capital in total, while cash flow to debt ratio is standing at 0.35. The debt to equity ratio resting at 0.78. The interest coverage ratio of the stock is -4.34.
Currently, EBITDA for the company is 157.58 million with net debt to EBITDA at 17.39. When we switch over and look at the enterprise to sales, we see a ratio of 1.87. The receivables turnover for the company is 6.9for trailing twelve months and the total asset turnover is 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.25.
Conclusion
To put it simply, Pacira BioSciences Inc (PCRX) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
